Eli Lilly and Company

Activity in this selectionAug 31, 2026 · Aug 1, 2026

By stage

Series A2

Series B2

Biotech4

United States4

4 in this selection

Aug 17

Develops neuro-metabolic therapeutics for schizophrenia and ALS

$30MSeries A

Role not disclosed

Aug 12

Clinical-stage biopharma developing injectable therapies for hair loss

$26MSeries B

Role not disclosed

Aug 12

Develops proximity-guided antibody-drug conjugate therapeutics for cancer and autoimmune disease

$77MSeries B

Role not disclosed

Aug 10

Develops durable protein therapeutics via gene therapy for chronic diseases

$10MSeries A

Role not disclosed